PAS
NBIX icon

Park Avenue Securities’s Neurocrine Biosciences NBIX Stock Holding History

Park Avenue Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Buy
8,601
+854
+11% +$127K 0.01% 796
2026
Q1 		$1.02M Sell
7,747
-543
-7% -$72K 0.01% 802
2025
Q4 		$1.18M Buy
8,290
+180
+2% +$26.1K 0.01% 737
2025
Q3 		$1.14M Buy
8,110
+16
+0.2% +$2.17K 0.01% 827
2025
Q2 		$1.02M Buy
8,094
+1,011
+14% +$116K 0.01% 777
2025
Q1 		$783K Buy
7,083
+3
+0% +$380 0.01% 694
2024
Q4 		$966K Buy
7,080
+1,336
+23% +$165K 0.01% 773
2024
Q3 		$662K Sell
5,744
-4,189
-42% -$574K 0.01% 862
2024
Q2 		$1.37M Buy
9,933
+363
+4% +$49.8K 0.02% 537
2024
Q1 		$1.32M Buy
9,570
+101
+1% +$13.8K 0.02% 540
2023
Q4 		$1.25M Buy
9,469
+528
+6% +$60.8K 0.02% 526
2023
Q3 		$1.01M Buy
+8,941
New +$942K 0.02% 557
2023
Q1 		– Sell
-8,553
Closed -$1.02M – 1006
2022
Q4 		$1.02M Buy
8,553
+31
+0.4% +$3.63K 0.02% 510
2022
Q3 		$905K Sell
8,522
-696
-8% -$70.6K 0.02% 488
2022
Q2 		$899K Buy
9,218
+1,300
+16% +$120K 0.02% 511
2022
Q1 		$742K Buy
7,918
+4,064
+105% +$344K 0.01% 588
2021
Q4 		$328K Sell
3,854
-1,923
-33% -$177K 0.01% 884
2021
Q3 		$554K Buy
5,777
+563
+11% +$53.2K 0.01% 598
2021
Q2 		$507K Buy
5,214
+1,136
+28% +$109K 0.01% 625
2021
Q1 		$397K Buy
4,078
+685
+20% +$71.8K 0.01% 666
2020
Q4 		$325K Buy
3,393
+317
+10% +$30.6K 0.01% 655
2020
Q3 		$296K Buy
3,076
+1,165
+61% +$135K 0.01% 576
2020
Q2 		$233K Buy
+1,911
New +$211K 0.01% 590

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Park Avenue Securities's NBIX Position: Q2 2026 in Review

Park Avenue Securities increased its Neurocrine Biosciences (NBIX) stake by 11% in Q2 2026, buying an estimated $127K and bringing the position to 8,601 shares worth $1.45M. The position accounts for 0.01% of the portfolio, ranked #796.

Park Avenue Securities first reported a position in NBIX in Q2 2020 and has held it in 23 quarters since. 243 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Park Avenue Securities held 8,601 shares of Neurocrine Biosciences worth $1.45M as of Q2 2026.
  • Park Avenue Securities bought 854 Neurocrine Biosciences shares in Q2 2026, an estimated $127K.
  • Neurocrine Biosciences made up 0.01% of Park Avenue Securities's portfolio in Q2 2026, its #796 holding.
  • Park Avenue Securities first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 23 quarters since.
  • 243 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.